Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
Abstract Type 2 diabetes mellitus (T2DM) is known to be associated with macrovascular (coronary heart disease, stroke, and peripheral arterial disease) and microvascular complications (diabetic kidney disease, retinopathy, and peripheral neuropathy). The coexistence of T2DM with established/risk of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-04-01
|
| Series: | Journal of Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/jod.jod_19_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586536759066624 |
|---|---|
| author | Soumitra Ray J Ezhilan Rajiv Karnik Ashish Prasad Rajashree Dhar |
| author_facet | Soumitra Ray J Ezhilan Rajiv Karnik Ashish Prasad Rajashree Dhar |
| author_sort | Soumitra Ray |
| collection | DOAJ |
| description | Abstract Type 2 diabetes mellitus (T2DM) is known to be associated with macrovascular (coronary heart disease, stroke, and peripheral arterial disease) and microvascular complications (diabetic kidney disease, retinopathy, and peripheral neuropathy). The coexistence of T2DM with established/risk of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease confers a poor prognosis, and management can be challenging. Guidelines recommend clinicians to consider CV/HF risk, renal/hepatic risk, and other comorbidities while choosing an antidiabetic regimen. The fixed dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors provides both glycemic and pleiotropic effects, including lower risk of hypoglycemia, lower rates of genitourinary tract infections, and weight neutrality. Based on CV risk, including HF, the combination of SGLT2i and DPP4i may be preferred over other conventional therapies (those with no CV benefit) in cases of established CV disease and/or HF risk. The Indian expert consensus group discussed the literature, clinical benefits, and the role of the FDC of Dapagliflozin and Sitagliptin for the unmet cardiovascular benefits in T2DM patients. This practical guidance document would support general physicians, endocrinologists, diabetologists, cardiologists, and nephrologists in selecting the appropriate regimen for superior patient outcomes. |
| format | Article |
| id | doaj-art-cdf6da97e8a945bb80c8267e0fb3959b |
| institution | Kabale University |
| issn | 2078-7685 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Diabetology |
| spelling | doaj-art-cdf6da97e8a945bb80c8267e0fb3959b2025-01-25T10:15:27ZengWolters Kluwer Medknow PublicationsJournal of Diabetology2078-76852024-04-0115213114110.4103/jod.jod_19_24Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes MellitusSoumitra RayJ EzhilanRajiv KarnikAshish PrasadRajashree DharAbstract Type 2 diabetes mellitus (T2DM) is known to be associated with macrovascular (coronary heart disease, stroke, and peripheral arterial disease) and microvascular complications (diabetic kidney disease, retinopathy, and peripheral neuropathy). The coexistence of T2DM with established/risk of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease confers a poor prognosis, and management can be challenging. Guidelines recommend clinicians to consider CV/HF risk, renal/hepatic risk, and other comorbidities while choosing an antidiabetic regimen. The fixed dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors provides both glycemic and pleiotropic effects, including lower risk of hypoglycemia, lower rates of genitourinary tract infections, and weight neutrality. Based on CV risk, including HF, the combination of SGLT2i and DPP4i may be preferred over other conventional therapies (those with no CV benefit) in cases of established CV disease and/or HF risk. The Indian expert consensus group discussed the literature, clinical benefits, and the role of the FDC of Dapagliflozin and Sitagliptin for the unmet cardiovascular benefits in T2DM patients. This practical guidance document would support general physicians, endocrinologists, diabetologists, cardiologists, and nephrologists in selecting the appropriate regimen for superior patient outcomes.https://doi.org/10.4103/jod.jod_19_24complicationsdiabetesdpp-4 inhibitorssglt2 inhibitorstype 2 diabetes |
| spellingShingle | Soumitra Ray J Ezhilan Rajiv Karnik Ashish Prasad Rajashree Dhar Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus Journal of Diabetology complications diabetes dpp-4 inhibitors sglt2 inhibitors type 2 diabetes |
| title | Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus |
| title_full | Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus |
| title_fullStr | Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus |
| title_full_unstemmed | Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus |
| title_short | Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus |
| title_sort | expert opinion on fixed dose combination of dapagliflozin plus sitagliptin for unmet cardiovascular benefits in type 2 diabetes mellitus |
| topic | complications diabetes dpp-4 inhibitors sglt2 inhibitors type 2 diabetes |
| url | https://doi.org/10.4103/jod.jod_19_24 |
| work_keys_str_mv | AT soumitraray expertopiniononfixeddosecombinationofdapagliflozinplussitagliptinforunmetcardiovascularbenefitsintype2diabetesmellitus AT jezhilan expertopiniononfixeddosecombinationofdapagliflozinplussitagliptinforunmetcardiovascularbenefitsintype2diabetesmellitus AT rajivkarnik expertopiniononfixeddosecombinationofdapagliflozinplussitagliptinforunmetcardiovascularbenefitsintype2diabetesmellitus AT ashishprasad expertopiniononfixeddosecombinationofdapagliflozinplussitagliptinforunmetcardiovascularbenefitsintype2diabetesmellitus AT rajashreedhar expertopiniononfixeddosecombinationofdapagliflozinplussitagliptinforunmetcardiovascularbenefitsintype2diabetesmellitus |